Hanall Pharmaceutical Co., Ltd.
Records under this name other than patents Hanall Pharmaceutical Co., Ltd. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Hanall Pharmaceutical Co., Ltd.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,722,674 | 1,3,5-Triazine-2,4,6-Triamine Compound or Pharmaceutical Acceptable Salt Thereof, and Pharmaceutical Composition Comprising the Same Formerly held Lapsed on the fee record Ended May 13, 2026 · High confidence | Lapsed on the fee record | Ended May 13, 2026 | High confidence |
| US 8,642,083 | Controlled release complex composition comprising angiotensin-II-receptor blockers and HMG-CoA reductase inhibitors Formerly held Lapsed on the fee record Ended Feb 4, 2026 · USPTO record | Lapsed on the fee record | Ended Feb 4, 2026 | USPTO record |
| US 8,541,474 | N,N-dimethyl imidodicarbonimidic diamide acetate, method for producing the same and pharmaceutical compositions comprising the same Formerly held Lapsed on the fee record Ended Sep 24, 2025 · USPTO record | Lapsed on the fee record | Ended Sep 24, 2025 | USPTO record |
| US 7,611,700 | Protease resistant modified interferon alpha polypeptides Formerly held Term ended Term ended Jan 19, 2025 · USPTO record | Term ended | Term ended Jan 19, 2025 | USPTO record |
| US 8,252,743 | Modified erythropoietin polypeptides and uses thereof for treatment Formerly held Lapsed on the fee record Ended Aug 28, 2024 · USPTO record | Lapsed on the fee record | Ended Aug 28, 2024 | USPTO record |
| US 8,222,209 | Modified growth hormones that exhibit increased protease resistance and pharmaceutical compositions thereof Formerly held Lapsed on the fee record Ended Jul 17, 2024 · USPTO record | Lapsed on the fee record | Ended Jul 17, 2024 | USPTO record |
| US 8,076,377 | N,N-dimethyl imidodicarbonimidic diamide dicarboxylate, method for producing the same and pharmaceutical compositions comprising the same Lapsed on the fee record Ended Dec 13, 2023 · USPTO record | Lapsed on the fee record | Ended Dec 13, 2023 | USPTO record |
| US 8,058,312 | N, N-dimethyl imidodicarbonimidic diamide acetate, method for producing the same and pharmaceutical compositions comprising the same Formerly held Lapsed on the fee record Ended Nov 15, 2023 · USPTO record | Lapsed on the fee record | Ended Nov 15, 2023 | USPTO record |
| US 8,114,839 | Protease resistant modified erythropoietin polypeptides Formerly held Term ended Term ended Sep 8, 2023 · USPTO record | Term ended | Term ended Sep 8, 2023 | USPTO record |
| US 7,998,469 | Protease resistant interferon beta mutants Formerly held Lapsed on the fee record Ended Aug 16, 2023 · USPTO record | Lapsed on the fee record | Ended Aug 16, 2023 | USPTO record |